Discover why LeMaitre's expansion in the peripheral vascular disease market and strong dividend growth make it an appealing ...

Third Quarter 2024 Results Key Financial Results Revenue: US$54.8m (up 16% from ...

BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:LMAT) announced today that management will be participating in ...

In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high ...

Lemaitre Vascular (LMAT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Daniel ...

For the current quarter ending in December, LeMaitre said it expects revenue in the range of $54.9 million to $56.9 million. The company expects full-year earnings to be $1.91 to $1.96 per share, with ...

LeMaitre Vascular (NASDAQ:LMAT) is scheduled to announce Q3 earnings results on Thursday, October 31st, after market close. The consensus EPS Estimate is $0.43 (+30.3% Y/Y) and the consensus Revenue ...

The goal of the device is to reduce vascular complications while simplifying the closure. Vivasure’s U.S. PATCH Clinical Study has enrolled over 145 patients across seventeen U.S. and European ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...